IDXX

Idexx Laboratories Inc /De

$557.02 +16.34 (+3.02%) At close · Jul 15

Market Cap

$44.49B

78,882,997

Up next

Next earnings call

Aug 5, 2026 Est · unconfirmed · in 3 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 5, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Buy Momentum Very Weak Sentiment Bullish Fundamentals Strong Quant / Vol Moderate

Market backdrop VIX 16.5 · calm Equity put/call 0.62

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg −11%

below

Price vs 50-day avg +0%

above

RSI (14) 51

neutral

MACD trend Positive

52-week position 19%

mid-range

Momentum

relative strength

Very Weak

1-month return −2%

trailing

6-month return −20%

trailing

YTD return −18%

this year

Relative strength −30%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $555 › 200d $625 — 200d above 50d

Institutional flow Accumulating

145 of 1,311 funds reported for Jun 30 · net +216.6K sh shares · +7 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

2.46% of float · ▼ -9.4% MoM · 2.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

1,311 holders — mid 3-yr range

Squeeze score 50

elevated · 0–100

Fundamentals

Strong

Revenue growth +10%

Y/Y

Gross margin 62%

expanding

EPS growth +23%

Y/Y

Free cash flow $1.1B

Valuation P/E 41.5

in line

Balance sheet $269.9M

net debt

Quant / Vol

risk profile

Moderate

Volatility 43%

annualized · 1-yr

Max drawdown −31%

past year

ATR 3.4%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record what management promised — and delivered

Latest guidance · from the 8-K filed May 5, 2026

Revenue · full year 2026 Maintained $4.68B – $4.76B

prior FY $4.3B midpoint +9.6% Y/Y

Reported revenue growth · full year 2026 Initiated 8.6% – 10.6%

Organic revenue growth · full year 2026 Maintained 7.7% – 9.7%

CAG Diagnostics Recurring Revenue Organic growth · full year 2026 Initiated 8.7% – 10.7%

EPS · full year 2026 Initiated $14.45 – $14.90

prior FY $13.08 midpoint +12.2% Y/Y

EPS Reported growth · full year 2026 Initiated 11% – 14%

EPS Comparable growth · full year 2026 Initiated 11% – 15%

Net interest expense · full year 2026 Initiated at least $34M

Share-based compensation tax benefit · full year 2026 Initiated at least $15M

Share-based compensation tax rate benefit · full year 2026 Initiated at least 1%

Effective tax rate · full year 2026 Initiated at least 21.4%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 3 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−11% Bearish

Price vs 50-day avg

+0% Bullish

RSI (14)

51 Neutral

MACD trend

Positive Bullish

52-week position

19% Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $555 › 200d $625 — 200d above 50d

Institutional flow Accumulating

145 of 1,311 funds reported for Jun 30 · net +216.6K sh shares · +7 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

2.46% of float · ▼ -9.4% MoM · 2.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

1,311 holders — mid 3-yr range

Price context

position in its 52-week range

52-wk low $507 Now $557 · 19% 52-wk high $770

vs 200-day avg -11% vs 50-day avg +0%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
CAG Diagnostics reoccurring revenue organic growth	11%	Q1 2026 call	—
CAG instrument revenue organic growth	28%	Q1 2026 call	—
CAG premium instrument placements	4,650	Q1 2026 call	—
CAG premium instrument placements growth	12%	Q1 2026 call	—
Comparable EPS growth non-GAAP	15%	Q1 2026 call	—
Comparable operating profit growth non-GAAP	15%	Q1 2026 call	—
Diagnostic imaging installations	330	Q1 2026 call	—
Free cash flow	$234M	Q1 2026 call	—
Global new and competitive catalyst placements	1,000	Q1 2026 call	—
IDEX InView DX analyzer placements	1,100	Q1 2026 call	—
International CAG Diagnostics recurring revenues organic growth	12%	Q1 2026 call	—
Net income to free cash flow conversion rate (trailing 12-month)	99%	Q1 2026 call	—
Non-well visits growth	20	Q1 2026 call	—
North America new and competitive catalyst placements	320	Q1 2026 call	—
U.S. organic CAG diagnostics recurring revenue growth	11%	Q1 2026 call	—
U.S. same-store clinical visits	-1%	Q1 2026 call	—
Wellness visits growth	-3%	Q1 2026 call	—
New and competitive Catalyst placements	1,400	fourth quarter 2025	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Diagnostics & Research — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
IDXX Idexx Laboratories Inc /De this stock	$44.49B	-17.7%	+10.4%	41.5	2.5%
TMO Thermo Fisher Scientific Inc.	$199.87B	-7.5%	+0.4%	29.6	1.4%
DHR Danaher Corp /De/	$142.11B	-11.9%	+8.5%	38.8	1.5%
NTRA Natera, Inc.	$39.30B	+21.1%	-2.8%	—	4.1%
A Agilent Technologies, Inc.	$37.94B	-0.6%	+6.4%	27.0	1.9%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

1,302

% held: 86.3%
Reported: 145 of 1,311
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

949

View

Short & Settlement

Short Interest Falling

Shares short

1.9M

Days to cover: 2.5d
Change: -200.4K sh

View

Short Volume

Short vol %

27%

As of: Jul 15, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $17.6K
As of: Jun 29, 2026

View

Off-Exchange

Off-exchange %

36.5%

Week of: Jun 22, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Sell

Member

April McClain Delaney

Amount: $1.0K–$15.0K
Traded: Jan 13, 2026

View

Financials

Revenue (FY)

$4.3B

Net income (FY): $1.1B
EPS diluted: $13.08

View

Buybacks

Authorized

shares 78.0M

Remaining: shares 3.7M

Spent Remaining

View

Filings

SEC Filings

Latest

8-K

Filed: May 15, 2026
This year: 9

View

Proposed Sales

Value

$1.1M

Shares: 1.8K
Filed: Mar 3, 2026

View

Earnings & Events

Earnings Calls Upcoming

Next call

Aug 13, 2026

Last call: May 5, 2026

View

Investor Relations

Upcoming events

View

Performance

	5D	20D	120D	MTD	YTD
IDXX	+0.2%	-2.0%	-20.0%	+5.8%	-17.7%
SPY	+1.3%	-0.2%	+10.1%	+1.1%	+10.7%
vs SPY	-1.0%	-1.8%	-30.2%	+4.7%	-28.4%

Capital returns

Buyback program · as of Dec 31, 2025

Authorized

shares 78.00M

Spent (derived)

shares 74.30M

Remaining

shares 3.70M

Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 874716 CUSIP 45168D104 13F (30d) 161 filings 134 filers Visit website Investor relations

IDXX

Price & Indicators

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns